About Us

Fresenius Kabi Global at a glance

Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

 

About us

Fresenius Kabi employs around 40,500 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2020, the company reported sales of around €7.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the  Fresenius SE & Co. KGaA healthcare group.

Key Figures 

€ in millions 2020 2019
Sales 6,976 6,919
EBITDA1 1,490 1,573
EBIT1 1,095 1,205
Net Income 1,2 730 797
Employees (Dec 31) 40,519 39,627

1 Before special terms
2  Net income attributes to shareholders of Fresenius SE & Co. KGaA